Review and update of benign prostatic hyperplasia in general practice
- 1 July 2018
- journal article
- review article
- Published by The Royal Australian College of General Practitioners in Australian Journal of General Practice
- Vol. 47 (7), 471-475
- https://doi.org/10.31128/afp-08-17-4292
Abstract
Background Benign prostatic hyperplasia (BPH) is the most common benign tumour in men. Although men with BPH often need medical or surgical management from a urologist at some point throughout the timeline of their disease, most men are initially assessed and managed by a general practitioner (GP) in the primary healthcare setting. Objectives The aim of this article is to highlight the principles of the pathogenesis, presentation, assessment and management of BPH in a primary care setting. Discussion Between 2009 and 2011, BPH was managed by GPs at approximately 228,000 general practice visits per annum in Australia. Several changes in pharmaceutical agents and surgical intervention have occurred over the past decade. As a result, it is imperative that GPs remain up to date with assessment and management of BPH, are aware of new therapies and understand when to refer to a urologist.Keywords
This publication has 13 references indexed in Scilit:
- Minimally invasive surgical therapies for benign prostatic hypertrophy: The rise in minimally invasive surgical therapiesProstate International, 2017
- Outcomes of transurethral resection and holmium laser enucleation in more than 60 g of prostate: A prospective randomized studyUrology Annals, 2017
- Prostatic Urethral Lift Improves Urinary Symptoms and Flow While Preserving Sexual Function for Men with Benign Prostatic Hyperplasia: A Systematic Review and Meta-analysisEuropean Urology, 2015
- Efficacy and safety of a fixed‐dose combination of dutasteride and tamsulosin treatment (Duodart®) compared with watchful waiting with initiation of tamsulosin therapy if symptoms do not improve, both provided with lifestyle advice, in the management of treatment‐naïve men with moderately symptomatic benign prostatic hyperplasia: 2‐year CONDUCT study resultsBJU International, 2015
- Transurethral plasmakinetic resection of the prostate is a reliable minimal invasive technique for benign prostate hyperplasia: a meta-analysis of randomized controlled trialsAsian Journal of Andrology, 2015
- Clinical outcomes after combined therapy with dutasteride plus tamsulosin or either monotherapy in men with benign prostatic hyperplasia (BPH) by baseline characteristics: 4‐year results from the randomized, double‐blind Combination of Avodart and Tamsulosin (CombAT) trialBJU International, 2011
- The Different Reduction Rate of Prostate-Specific Antigen in Dutasteride and FinasterideKorean Journal of Urology, 2010
- The impact of self‐management of lower urinary tract symptoms on frequency‐volume chart measuresBJU International, 2009
- A review of the clinical efficacy and safety of 5α-reductase inhibitors for the enlarged prostateClinical Therapeutics, 2007
- Self management for men with lower urinary tract symptoms: randomised controlled trialBMJ, 2006